159 related articles for article (PubMed ID: 19147567)
1. Noncationic peptides obtained from azurin preferentially enter cancer cells.
Taylor BN; Mehta RR; Yamada T; Lekmine F; Christov K; Chakrabarty AM; Green A; Bratescu L; Shilkaitis A; Beattie CW; Das Gupta TK
Cancer Res; 2009 Jan; 69(2):537-46. PubMed ID: 19147567
[TBL] [Abstract][Full Text] [Related]
2. Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity.
Yamada T; Fialho AM; Punj V; Bratescu L; Gupta TK; Chakrabarty AM
Cell Microbiol; 2005 Oct; 7(10):1418-31. PubMed ID: 16153242
[TBL] [Abstract][Full Text] [Related]
3. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.
Mehta RR; Hawthorne M; Peng X; Shilkaitis A; Mehta RG; Beattie CW; Das Gupta TK
Cancer Prev Res (Phila); 2010 Oct; 3(10):1351-60. PubMed ID: 20841487
[TBL] [Abstract][Full Text] [Related]
4. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.
Chaudhari A; Mahfouz M; Fialho AM; Yamada T; Granja AT; Zhu Y; Hashimoto W; Schlarb-Ridley B; Cho W; Das Gupta TK; Chakrabarty AM
Biochemistry; 2007 Feb; 46(7):1799-810. PubMed ID: 17249693
[TBL] [Abstract][Full Text] [Related]
5. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.
Mehta RR; Yamada T; Taylor BN; Christov K; King ML; Majumdar D; Lekmine F; Tiruppathi C; Shilkaitis A; Bratescu L; Green A; Beattie CW; Das Gupta TK
Angiogenesis; 2011 Sep; 14(3):355-69. PubMed ID: 21667138
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
[TBL] [Abstract][Full Text] [Related]
7. Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy.
Mahfouz M; Hashimoto W; Das Gupta TK; Chakrabarty AM
Plasmid; 2007 Jan; 57(1):4-17. PubMed ID: 17166586
[TBL] [Abstract][Full Text] [Related]
8. Biological evaluation of penetration domain and killing domain peptides.
Jarajapu YP; Baltunis J; Knot HJ; Sullivan SM
J Gene Med; 2005 Jul; 7(7):908-17. PubMed ID: 15832372
[TBL] [Abstract][Full Text] [Related]
9. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Huq A; Singh B; Meeker T; Mascarenhas D
Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
[TBL] [Abstract][Full Text] [Related]
10. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.
Yamada T; Mehta RR; Lekmine F; Christov K; King ML; Majumdar D; Shilkaitis A; Green A; Bratescu L; Beattie CW; Das Gupta TK
Mol Cancer Ther; 2009 Oct; 8(10):2947-58. PubMed ID: 19808975
[TBL] [Abstract][Full Text] [Related]
11. Anti-melanoma activity of hybrid peptide P18 and its mechanism of action.
Huang W; Lu L; Shao X; Tang C; Zhao X
Biotechnol Lett; 2010 Apr; 32(4):463-9. PubMed ID: 19957017
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Actions of Azurin and Its Derived Peptide p28.
Huang F; Shu Q; Qin Z; Tian J; Su Z; Huang Y; Gao M
Protein J; 2020 Apr; 39(2):182-189. PubMed ID: 32180097
[TBL] [Abstract][Full Text] [Related]
13. Bacterial proteins as potential drugs in the treatment of leukemia.
Kwan JM; Fialho AM; Kundu M; Thomas J; Hong CS; Das Gupta TK; Chakrabarty AM
Leuk Res; 2009 Oct; 33(10):1392-9. PubMed ID: 19250673
[TBL] [Abstract][Full Text] [Related]
14. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin.
Santini S; Bizzarri AR; Cannistraro S
J Mol Recognit; 2011; 24(6):1043-55. PubMed ID: 22038811
[TBL] [Abstract][Full Text] [Related]
15. p28, a first in class peptide inhibitor of cop1 binding to p53.
Yamada T; Christov K; Shilkaitis A; Bratescu L; Green A; Santini S; Bizzarri AR; Cannistraro S; Gupta TK; Beattie CW
Br J Cancer; 2013 Jun; 108(12):2495-504. PubMed ID: 23736031
[TBL] [Abstract][Full Text] [Related]
16. Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface.
Iwasaki T; Ishibashi J; Tanaka H; Sato M; Asaoka A; Taylor D; Yamakawa M
Peptides; 2009 Apr; 30(4):660-8. PubMed ID: 19154767
[TBL] [Abstract][Full Text] [Related]
17. Highly efficient, nonpeptidic oligoguanidinium vectors that selectively internalize into mitochondria.
Fernández-Carneado J; Van Gool M; Martos V; Castel S; Prados P; de Mendoza J; Giralt E
J Am Chem Soc; 2005 Jan; 127(3):869-74. PubMed ID: 15656624
[TBL] [Abstract][Full Text] [Related]
18. Structure and function of a custom anticancer peptide, CB1a.
Wu JM; Jan PS; Yu HC; Haung HY; Fang HJ; Chang YI; Cheng JW; Chen HM
Peptides; 2009 May; 30(5):839-48. PubMed ID: 19428759
[TBL] [Abstract][Full Text] [Related]
19. The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine.
Schröder-Borm H; Bakalova R; Andrä J
FEBS Lett; 2005 Nov; 579(27):6128-34. PubMed ID: 16269280
[TBL] [Abstract][Full Text] [Related]
20. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides.
Makovitzki A; Fink A; Shai Y
Cancer Res; 2009 Apr; 69(8):3458-63. PubMed ID: 19351852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
